Isabel Lastres-Becker1,2, Angel J García-Yagüe1,2, Robert H Scannevin3, María J Casarejos4, Sebastian Kügler5, Alberto Rábano6, Antonio Cuadrado1,2. 1. 1 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigación Sanitaria La Paz (IdiPaz), Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC , Madrid, Spain . 2. 2 Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid , Madrid, Spain . 3. 3 Biogen, Neurology Research , Cambridge, Massachusetts. 4. 4 Servicio de Neurobiología-Investigación, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) , Madrid, Spain . 5. 5 Department of Neurology, Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medicine Göttingen , Göttingen, Germany . 6. 6 Department of Neuropathology and Tissue Bank, Unidad de Investigación Proyecto Alzheimer, Fundación CIEN, Instituto de Salud Carlos III , Madrid, Spain .
Abstract
AIMS: This preclinical study was aimed at determining whether pharmacological targeting of transcription factor NRF2, a master controller of many homeostatic genes, might provide a disease-modifying therapy in the animal model of Parkinson's disease (PD) that best reproduces the main hallmark of this pathology, that is, α-synucleinopathy, and associated events, including nigral dopaminergic cell death, oxidative stress, and neuroinflammation. RESULTS: Pharmacological activation of NRF2 was achieved at the basal ganglia by repurposing dimethyl fumarate (DMF), a drug already in use for the treatment of multiple sclerosis. Daily oral gavage of DMF protected nigral dopaminergic neurons against α-SYN toxicity and decreased astrocytosis and microgliosis after 1, 3, and 8 weeks from stereotaxic delivery to the ventral midbrain of recombinant adeno-associated viral vector expressing human α-synuclein. This protective effect was not observed in Nrf2-knockout mice. In vitro studies indicated that this neuroprotective effect was correlated with altered regulation of autophagy markers SQTSM1/p62 and LC3 in MN9D, BV2, and IMA 2.1 and with a shift in microglial dynamics toward a less pro-inflammatory and a more wound-healing phenotype. In postmortem samples of PD patients, the cytoprotective proteins associated with NRF2 expression, NQO1 and p62, were partly sequestered in Lewy bodies, suggesting impaired neuroprotective capacity of the NRF2 signature. INNOVATION: These experiments provide a compelling rationale for targeting NRF2 with DMF as a therapeutic strategy to reinforce endogenous brain defense mechanisms against PD-associated synucleinopathy. CONCLUSION: DMF is ready for clinical validation in PD. Antioxid. Redox Signal. 25, 61-77.
AIMS: This preclinical study was aimed at determining whether pharmacological targeting of transcription factor NRF2, a master controller of many homeostatic genes, might provide a disease-modifying therapy in the animal model of Parkinson's disease (PD) that best reproduces the main hallmark of this pathology, that is, α-synucleinopathy, and associated events, including nigral dopaminergic cell death, oxidative stress, and neuroinflammation. RESULTS: Pharmacological activation of NRF2 was achieved at the basal ganglia by repurposing dimethyl fumarate (DMF), a drug already in use for the treatment of multiple sclerosis. Daily oral gavage of DMF protected nigral dopaminergic neurons against α-SYN toxicity and decreased astrocytosis and microgliosis after 1, 3, and 8 weeks from stereotaxic delivery to the ventral midbrain of recombinant adeno-associated viral vector expressing human α-synuclein. This protective effect was not observed in Nrf2-knockout mice. In vitro studies indicated that this neuroprotective effect was correlated with altered regulation of autophagy markers SQTSM1/p62 and LC3 in MN9D, BV2, and IMA 2.1 and with a shift in microglial dynamics toward a less pro-inflammatory and a more wound-healing phenotype. In postmortem samples of PDpatients, the cytoprotective proteins associated with NRF2 expression, NQO1 and p62, were partly sequestered in Lewy bodies, suggesting impaired neuroprotective capacity of the NRF2 signature. INNOVATION: These experiments provide a compelling rationale for targeting NRF2 with DMF as a therapeutic strategy to reinforce endogenous brain defense mechanisms against PD-associated synucleinopathy. CONCLUSION:DMF is ready for clinical validation in PD. Antioxid. Redox Signal. 25, 61-77.
Authors: María Dolores Martín-de-Saavedra; Josiane Budni; Mauricio P Cunha; Vanessa Gómez-Rangel; Silvia Lorrio; Laura Del Barrio; Isabel Lastres-Becker; Esther Parada; Rosa María Tordera; Ana Lùcia S Rodrigues; Antonio Cuadrado; Manuela G López Journal: Psychoneuroendocrinology Date: 2013-04-23 Impact factor: 4.905
Authors: K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima Journal: Biochem Biophys Res Commun Date: 1997-07-18 Impact factor: 3.575
Authors: Ana I Rojo; Gethin McBean; Marina Cindric; Javier Egea; Manuela G López; Patricia Rada; Neven Zarkovic; Antonio Cuadrado Journal: Antioxid Redox Signal Date: 2014-05-05 Impact factor: 8.401
Authors: Isabel Lastres-Becker; Nadia G Innamorato; Tomasz Jaworski; Alberto Rábano; Sebastian Kügler; Fred Van Leuven; Antonio Cuadrado Journal: Brain Date: 2013-11-25 Impact factor: 13.501
Authors: Christopher Czaniecki; Tammy Ryan; Morgan G Stykel; Jennifer Drolet; Juliane Heide; Ryan Hallam; Shalandra Wood; Carla Coackley; Keith Sherriff; Craig D C Bailey; Scott D Ryan Journal: Proc Natl Acad Sci U S A Date: 2019-06-24 Impact factor: 11.205
Authors: Jonathan D Cherry; Ahmad Zeineddin; Eric B Dammer; James A Webster; Duc Duong; Nicholas T Seyfried; Allan I Levey; Victor E Alvarez; Bertrand R Huber; Thor D Stein; Patrick T Kiernan; Ann C McKee; James J Lah; Chadwick M Hales Journal: J Neuropathol Exp Neurol Date: 2018-01-01 Impact factor: 3.685
Authors: Lei Liu; Mary K Vollmer; Abdullah S Ahmad; Victoria M Fernandez; Hocheol Kim; Sylvain Doré Journal: Free Radic Biol Med Date: 2018-11-17 Impact factor: 7.376